查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840747

鼻腔给药和疫苗市场（按药物类型、剂型、装置类型、剂量、应用和最终用户划分）－2025-2032年全球预测

Intranasal Drug & Vaccine Delivery Market by Drug Type, Formulation Type, Device Type, Dosage, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，鼻腔给药和疫苗输送市场规模将达到 796.1 亿美元，复合年增长率为 6.09%。

关键市场统计数据
基准年 2024 495.9亿美元
预计年份：2025年 524.3亿美元
预测年份 2032 796.1亿美元
复合年增长率 (%) 6.09%

权威的鼻腔治疗药物和疫苗说明，概述了科学前景、实际限制以及产品开发的战略考量

鼻腔给药已成为製剂科学、器材工程和以病人为中心的医疗理念交叉领域的重要策略性给药方式。过去十年，黏膜免疫学、製剂稳定剂和精准给药装置的进步，使鼻腔给药从小众替代方案转变为治疗药物和疫苗的主流选择。随着临床研发管线的成熟，製药、生物技术和医疗器材製造领域的相关人员正在调整其临床开发计划、监管策略和商业策略，以充分体现鼻腔给药的独特优势和限制。

本导言将鼻腔给药置于更广泛的治疗生态系中，重点介绍其优势，包括某些分子可快速全身吸收、非侵入性给药可提高患者依从性，以及能够诱导针对呼吸道病原体的强效粘膜免疫反应。同时，本导言也指出了持续影响专案设计的许多技术难题，例如製剂的黏度和稳定性、装置引起的沉积差异、多重药物合併治疗与单一药物治疗的剂量重复性，以及复杂生技药品的冷链管理等。透过阐述机会与挑战，本部分旨在帮助读者理解监管沟通、生产低温运输和市场推广计画等策略性权衡。

本执行摘要从基础科学入手，探讨了重塑格局的关键变化，分析了不断演变的贸易政策和供应链之间的相互联繫，并将市场细分和区域动态转化为对开发商和投资者的实际商业性影响。

技术、临床和商业方面的关键因素正在汇聚，使鼻腔给药成为疫苗和标靶治疗的策略性给药方式。

鼻腔给药正受到技术、临床和商业性因素共同作用的重塑。首先，製剂科学的进步使得稳定的液体和粉末製剂得以实现，从而扩大了可透过鼻粘膜递送的生物活性分子种类。同时，从精密雾化器到低变异性定量吸入器，装置工程的进步正在降低剂量不确定性并提高药物靶向沉积率。

临床证据也正在改变人们的认知。经鼻吸入型疫苗候选药物的新兴免疫抗原性数据表明，鼻腔疫苗可能增强针对呼吸道病原体的黏膜免疫力，从而补充肠外疫苗引起的全身免疫反应。鼻腔给药途径正被探索用于治疗神经系统疾病和疼痛管理，它能够快速使药物作用于中枢神经系统，同时最大限度地减少全身副作用。在商业性，患者对非侵入性给药方式的偏好以及居家照护带来的营运效率，正迫使支付方和医疗服务提供者重新思考处方分配和门诊治疗路径。总而言之，这些进展正在改变专案的优先顺序，促进製剂和器械专家之间的伙伴关係，并推动供应链重组，以支持对低温运输敏感的生技药品和敏感器械组件的采购。

2025 年关税格局如何重塑鼻内给药价值链的采购、生产在地化和策略供应商多元化？

2025年，美国征收的关税累积效应为全球鼻用药物及给药装置的供应链带来了显着的复杂性。对进口零件（例如雾化器专用聚合物、雾化器精密金属零件以及某些原料药前驱物）征收的关税，加剧了到岸成本的波动，促使采购团队重新评估采购区域。製造商面临权衡取舍：是自行承担增加的成本、将成本转嫁给下游环节，还是投资于短期内实现生产和组装的本地化，以保护利润并规避关税的影响。

这些压力对监管和策略规划产生了连锁反应。研发团队在供应商合约中加入了紧急采购条款，并加快了备选供应商的资格审核，以确保临床试验的连续性。对于依赖复杂供应链取得mRNA组分和低温运输耗材的疫苗研发企业而言，关税环境促使奖励将生产营运集中在本国或盟国境内，以降低边境风险。同时，合约研发受託製造厂商等服务提供者也透过扩大区域产能和提供考虑关税因素的筹资策略来应对，从而最大限度地减少营运中断。

展望未来，关税驱动的成本动态正在再形成设备选择和给药方式的决策。当关税影响到初级包装和设备组件时，企业正在权衡重新配製单剂量製剂所需的资本密集度，以及多剂量给药系统的物流复杂性和潜在成本优势。最终，关税环境正在加速战略本地化，将供应商多元化提升为董事会层面的关注点，并鼓励企业主动参与政策制定，为生命科学关键组件寻求豁免和优惠分类。

详细的細項分析揭示了药物类别、製剂、器材、剂型、临床用途和最终用户特征如何决定药物开发策略。

深入分析鼻腔製剂的细分市场，可以发现其发展机会和技术要求多种多样。从药物类型来看，该领域涵盖多种子类别，例如镇痛药（非阿片类和阿片类）、抗组织胺、类固醇、疫苗、灭活疫苗、减毒疫苗以及基于mRNA的候选疫苗。镇痛药强调快速吸收和良好的耐受性，抗组织胺药物和类固醇则优先考虑局部疗效和粘膜滞留，而疫苗则需要稳定性、佐剂相容性和抗原性保持能力。凝胶製剂可延长药物与黏膜的接触时间，液体製剂可与现有的定量给药装置配合使用，而粉末製剂则具有耐热性并简化了低温运输物流。

装置类型同样重要：雾化器平台可实现适用于更广泛粘膜覆盖的细颗粒分散，而滴鼻剂虽然给药简单且成本低廉，但剂量精度有限。剂型选择（多剂量或单剂量）不仅影响患者的便利性，也影响监管和防腐策略，进而影响保存期限和微生物安全性。过敏治疗、荷尔蒙替代疗法、神经系统疾病、疼痛管理、精神疾病和药物传递——每种疗法都有其独特的临床终点、真实世界中的依从性以及报销方面的考虑。不同的终端使用者——居家医疗、医院/诊所和研究/学术机构——决定了部署模式、培训要求和装置稳健性规范。这些相互交织的细分维度共同决定了计画的启动/终止、临床终点的优化以及最有可能提供稳定治疗效果的装置和製剂组合的选择。

比较区​​域动态如何影响主要全球市场的监管方式、生产布局和商业化策略

区域动态对发展重点、监管策略和商业化蓝图有显着影响。在美洲，强大的临床试验基础设施以及公共和私人机构对呼吸道疫苗和新型止痛药製剂的大量投资，正推动着鼻内给药创新技术的快速普及。关键市场的监管路径强调可靠的临床终点和上市后监测，这加速了证据的产生，但也要求及早规划真实世界数据的收集和与支付方的沟通。同时，该地区的製造生态系统正日益转向模组化设施设计和製造外包伙伴关係，以适应生物製药和医疗器材的整合。

欧洲、中东和非洲地区（EMEA）的监管格局呈现出分散的特点，涉及多个司法管辖区，每个司法管辖区对器械-药物组合应用和粘膜疫苗的临床证据都有不同的要求。由于部分市场面临物流挑战，该地区对低温运输的粉末製剂表现出浓厚的兴趣。该地区的相关人员通常优先考虑成本效益和公共卫生采购动态，这会影响商业性定价策略和可扩展疫苗宣传活动的规划。

亚太地区人口密度高、疾病负担多样，且生物製药生产能力快速扩张，这为大规​​模疫苗推广和主导的鼻内给药疗法的引入提供了极具吸引力的案例研究。区域性的生产激励措施和积极的公私合作有助于加速临床项目，而该地区在医疗器材组件製造方面的供应链优势则为垂直整合提供了机会。总而言之，这些地区在市场进入、伙伴关係模式和监管路径方面呈现出差异化的特点，必须与製造地选址和分销模式相匹配。

製药创新者、器材设计者、合约研发生产机构 (CDMO) 和生物技术新参与企业之间的策略行动和竞争动态将决定鼻腔给药领域的领导地位。

产业主要参与者包括大型跨国製药公司、专业设备製造商、合约研发受託製造厂商 ( CDMO) 以及专注于黏膜免疫学和製剂科学的敏捷生物技术创新者。领先企业正在采取几项通用的策略性倡议：在研发管线早期整合器材和製剂开发，以降低后期相容性风险；与学术中心建立多学科合作关係，以充分利用对黏膜免疫机制的深入了解；以及投资于可扩展的液体和粉末疫苗填充和包装能力。此外，服务供应商透过提供满足器械-药物组合产品独特需求的全面监管和品质服务包来脱颖而出。

竞争对手正致力于围绕新型给药机制、黏合剂化学和雾化器技术培育智慧财产权，部分企业也寻求适用于止痛药、荷尔蒙疗法和疫苗建构的平台策略。以病人为中心的设计——例如给药便利性、剂量精准性和便携性——正成为衡量商业性成功的关键指标，尤其是在居家医疗日益普及的情况下。最后，策略性併购和授权协议经常被用于整合製剂专业知识和市场推广能力，从而加速临床应用，同时将研发风险分担给合作伙伴。

为加速临床和商业性成功，提出切实可行的策略建议，以协调设备共同开发、供应链韧性、配方选择和证据产生。

产业领导者应采取多管齐下的方法，将科学严谨性与商业性实用性结合。首先，从一开始就优先考虑一体化的设备和配方开发，以避免可能延误监管申报的下游相容性问题。其次，拓展关键零件的供应商网络，并寻找本地製造合作伙伴，以降低关税和地缘政治风险，同时透过平行工艺验证合格二级供应商，从而确保临床实验的连续性。

第三，由于製剂选择直接影响低温运输负担、分销策略和病患接受度，我们将投入资源进行一项完善的稳定性研究项目，并行评估液体、凝胶和粉末三种製剂方案。第四，我们将采用适应性临床设计和真实世界证据策略，以明确疫苗在黏膜和全身终点以及治疗适应症方面的动态结果。第五，我们将与学术界、医疗器材专家和合约研发生产机构（CDMO）建立策略联盟，以加速平台成熟并共用研发风险。最后，我们将儘早纳入患者和医护人员体验指标，以指导器械的人体工学设计和培训材料，并确保在居家医疗和门诊病人环境中的商业性部署得到清晰的使用指南和依从性监测途径的支持。

采用综合研究途径，结合一手访谈、技术文献综述、法规分析和三角验证，以检验可用于鼻腔给药计画的实际可行的见解。

本执行摘要的研究整合了第一手访谈、二手文献、监管指南和技术检验，旨在建构对鼻腔给药的全面、多角度的理解。第一手研究包括对製剂科学家、器材工程师、法规事务专业人员、采购负责人和临床终端使用者进行结构化访谈，以了解实际限制、推广应用驱动因素和新兴的临床优先事项。二级资讯来源，包括关于粘膜免疫学的同行评审文献、关于组合药物的官方监管指南以及关于喷雾和粉剂给药技术的技术白皮书，有助于将第一手研究成果置于更广阔的背景中进行解读。

透过将访谈结果与监管文件和设备製造商的技术规格进行交叉比对，实施了资料三角验证，以确保所宣称的设备性能与观察到的临床需求相符。品质保证措施包括专家评审小组和供应链假设的情境压力测试，特别关注关税和本地化影响。调查方法的局限性包括：虽然这种方法强调深度和交叉检验，但可能无法充分体现具体的合约和独特的生产细节。儘管如此，该调查方法仍为鼻用药物产品生命週期中的策略决策提供了全面、实证的基础。

一份权威的综合报告，重点阐述了将鼻内创新转化为临床和商业性可行的产品所需的实际必要条件和战略路径。

鼻腔给药正处于策略曲折点，科学前景与实际应用挑战并存。製剂化学和装置精度的进步正在拓展该方法在疫苗和各种治疗适应症中的效用，而关税调整和供应链中断则凸显了筹资策略和生产布局决策的重要性。细分市场分析表明，成功取决于对药物类型、製剂形式、装置选择、给药方式、预期用途和最终用户情况的精心定制。

这意味着要儘早整合设备和配方，在必要时建立具有韧性的社区供应链，并关注黏膜和真实世界疗效终点，从而产生能够引起监管机构和支付方共鸣的证据。在这些领域取得卓越成效，将使那些能够把鼻科科学的最新进展转化为患者和医疗保健系统可及且有效的产品的领导者脱颖而出。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 用于延长鼻腔药物滞留时间的黏膜附着性聚合物系统的研究进展
  • 利用气溶胶奈米载体增强经鼻给药的脑部标靶递送
  • 整合3D列印技术製造个人化滴鼻药剂
  • 鼻腔给药减毒活病毒疫苗的临床进展表明，其能增强黏膜免疫力。
  • 一种采用速效小分子製剂的新型经鼻偏头痛治疗方法
  • 鼻用胰岛素喷剂扩大临床试验范围，用于治疗神经退化性疾病
  • 利用先进的喷雾冷冻干燥技术大规模生产干粉经鼻吸入型疫苗
  • 製药和医疗设备製造商携手合作，优化鼻喷雾给药系统
  • 采用即时成像技术监测鼻内沉积和吸收情况

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按药物类型分類的鼻腔给药和疫苗市场

  • 止痛药
    • 非阿片类药物
    • 阿片类药物
  • 抗组织胺药
  • 类固醇
  • 疫苗
    • 灭活疫苗
    • 减毒活疫苗
    • 基于mRNA的疫苗

9. 按剂型分類的鼻腔药物和疫苗递送市场

  • 凝胶配方
  • 液体配方
  • 粉末製剂

第十章 依设备类型分類的鼻腔药物和疫苗传输市场

  • 雾化器
  • 鼻滴管
  • 鼻喷剂

11. 按剂量分類的鼻腔给药和疫苗市场

  • 多剂量
  • 单一剂量

第十二章 按应用分類的鼻腔药物和疫苗递送市场

  • 过敏治疗
  • 荷尔蒙补充疗法
  • 神经系统疾病
  • 疼痛管理
  • 精神疾病
  • 治疗性药物递送

第十三章 依最终用户分類的鼻腔药物和疫苗递送市场

  • 居家照护
  • 医院和诊所
  • 研究和学术机构

第十四章 各地区鼻腔药物及疫苗传输市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按组别分類的鼻腔药物和疫苗递送市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国鼻腔给药及疫苗市场概况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Altimmune, Inc.
    • AptarGroup, Inc.
    • AstraZeneca PLC
    • Bausch Health Companies Inc.
    • Bayer AG
    • Becton, Dickinson, and Company
    • Bharat Biotech Ltd.
    • Boehringer Ingelheim International GmbH.
    • Catalent, Inc
    • DCA Design International Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline PLC
    • Hovione Limited
    • Impel Pharmaceuticals LLC.
    • Indivior PLC
    • Intersect ENT by Medtronic plc
    • Intertek Group PLC
    • Johnson & Johnson Services, Inc.
    • Kindeva Drug Delivery LP
    • Merck & Co., Inc.
    • Neurelis, Inc.
    • Novartis AG
    • OptiNose, Inc.
    • Pfizer Inc.
    • Recipharm AB.
    • Sanofi SA
    • Teleflex Incorporated
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A339DAEFA961

The Intranasal Drug & Vaccine Delivery Market is projected to grow by USD 79.61 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 49.59 billion
Estimated Year [2025] USD 52.43 billion
Forecast Year [2032] USD 79.61 billion
CAGR (%) 6.09%

An authoritative orientation to intranasal therapeutics and vaccines that frames scientific promise, practical constraints, and strategic considerations for product development

Intranasal delivery has emerged as a strategic modality at the intersection of drug formulation science, device engineering, and patient-centric care. Over the past decade, advances in mucosal immunology, formulation stabilizers, and precision dosing devices have repositioned the nasal route from a niche alternative to a mainstream consideration for both therapeutic drugs and vaccines. As clinical pipelines mature, stakeholders across pharmaceutical, biotech, and device manufacturing spheres are recalibrating clinical development plans, regulatory approaches, and commercial strategies to reflect the distinctive advantages and constraints of the nasal route.

This introduction situates intranasal delivery within the broader therapeutic ecosystem by highlighting its appeal: rapid systemic absorption for certain molecules, noninvasive administration that enhances patient adherence, and the potential to elicit robust mucosal immune responses for respiratory pathogens. At the same time, it recognizes the technical hurdles that continue to shape program design, including formulation viscosity and stability, device-driven deposition variability, dose reproducibility in multi-dose versus unit-dose formats, and cold-chain considerations for complex biologics. By framing both the opportunities and constraints, this section prepares readers to appreciate the strategic trade-offs that follow in regulatory engagement, manufacturing investments, and market access planning.

Transitioning from the foundational science to practical deployment, the rest of this executive summary unpacks the major shifts reshaping the landscape, explores how evolving trade policies intersect with supply chains, and maps segmentation and regional dynamics to pragmatic commercial implications for developers and investors.

Key converging technological, clinical, and commercial drivers that are transforming intranasal delivery into a strategic modality for vaccines and targeted therapeutics

The intranasal landscape is being reshaped by converging technological, clinical, and commercial forces that collectively elevate the modality beyond incremental improvement to a transformative pathway for specific indications. First, formulation science has advanced to allow stable liquid and powder presentations that extend the range of biologically active molecules deliverable via the nasal mucosa; innovations in mucoadhesives and permeation enhancers are enabling higher bioavailability for peptides and select biologics. Concurrently, device engineering developments-from precision atomizers to low-variability metered sprays-are reducing dosing uncertainty and improving targeted deposition, which in turn influences clinical design and regulatory strategy.

Clinical evidence has also shifted perceptions. Emerging immunogenicity data for intranasal vaccine candidates suggest the potential for stronger mucosal immunity against respiratory pathogens, complementing systemic responses elicited by parenteral vaccines. For therapeutic agents addressing neurological conditions or pain management, intranasal routes are being explored for their ability to enable rapid CNS exposure while minimizing systemic side effects. Commercially, patient preference for noninvasive administration and the operational efficiencies of homecare delivery are prompting payers and providers to reassess formulary placement and outpatient treatment pathways. Taken together, these developments are transforming program prioritization, catalyzing partnerships across formulation and device specialists, and prompting supply-chain reconfiguration to support cold-chain sensitive biologics and precision device-component sourcing.

How the 2025 tariff landscape has reshaped procurement, manufacturing localization, and strategic supplier diversification across the intranasal delivery value chain

In 2025, the cumulative effect of tariffs imposed by the United States introduced material complexities into global supply chains for intranasal pharmaceuticals and delivery devices. Tariffs on imported components, including specialized polymers for sprayers, precision metal parts for atomizers, and certain active pharmaceutical ingredient precursors, increased landed cost variability and prompted procurement teams to re-evaluate sourcing geographies. Manufacturers faced trade-offs between absorbing incremental costs, passing them downstream, or investing in near-term localization of manufacturing and assembly to preserve margin and avoid tariff exposure.

These pressures have had ripple effects on regulatory and strategic planning. Development teams incorporated contingency sourcing clauses into supplier agreements and accelerated qualification of alternate vendors to maintain clinical trial continuity. For vaccine developers reliant on complex supply chains for mRNA components and cold-chain consumables, the tariff environment intensified incentives to consolidate manufacturing steps domestically or within allied jurisdictions to mitigate border risk. At the same time, service providers such as contract development and manufacturing organizations responded by expanding regional capacity and offering tariff-aware sourcing strategies to minimize operational disruption.

Looking ahead, tariff-driven cost dynamics are reshaping decisions about device choice and dosage format. Companies are weighing the capital intensity of retooling for unit-dose formats against the logistical complications and potential cost advantages of multi-dose systems when tariffs affect primary packaging or device components. Ultimately, the tariff environment has accelerated strategic localization, elevated supplier diversification as a board-level concern, and encouraged preemptive policy engagement to seek exemptions or favorable classifications for life-science critical components.

In-depth segmentation insights revealing how drug class, formulation, device, dosage format, clinical application, and end-user profile jointly determine development strategies

A granular view of segmentation reveals the heterogeneity of opportunity and technical requirements across intranasal programs. When examining drug type, the field encompasses Analgesics-studied across Non-opioids and Opioids-alongside Antihistamines, Steroids, and Vaccines with subcategories that include Inactivated Vaccines, Live Attenuated Vaccines, and mRNA-based Vaccine candidates. Each class imposes distinct formulation imperatives: analgesic molecules emphasize rapid absorption profiles and tolerability, antihistamines and steroids prioritize local effect and mucosal retention, while vaccines demand stability, adjuvant compatibility, and preservation of antigenicity. Formulation type further differentiates development pathways, with Gel Formulations offering prolonged mucosal contact, Liquid Formulations supporting established metered-dosing devices, and Powder Formulations presenting options for thermostability and simplified cold-chain logistics.

Device type is equally determinative: Atomizer platforms enable fine-particle dispersion suitable for broader mucosal coverage; Nasal Droppers provide simple, low-cost administration but with limited dosing precision; Nasal Spray devices balance dose control with patient familiarity. Dosage format choices between Multi-dose and Unit-dose influence not only patient convenience but also regulatory and preservative strategies, impacting shelf life and microbiological safeguards. Application segmentation spans Allergy Treatment, Hormone Replacement, Neurological Conditions, Pain Management, Psychiatric Disorders, and Therapeutic Drug Delivery, each with unique clinical endpoints, real-world adherence profiles, and reimbursement considerations. End-user distinctions among Homecare, Hospitals & Clinics, and Research & Academic Institution determine deployment models, training requirements, and device robustness specifications. Together, these intersecting segmentation axes inform go/no-go decisions, optimization of clinical endpoints, and the selection of device-formulation pairings most likely to deliver consistent therapeutic outcomes.

Comparative regional dynamics that shape regulatory approaches, manufacturing footprints, and commercialization strategies across major global markets

Regional dynamics exert a powerful influence on development priorities, regulatory tactics, and commercialization roadmaps. In the Americas, strong clinical trial infrastructure and substantial private and public investment into respiratory vaccines and novel analgesic formulations drive rapid adoption of intranasal innovations. Regulatory pathways in major markets emphasize robust clinical endpoints and post-marketing surveillance, which accelerates evidence generation but requires early planning for real-world data capture and payer engagement. Meanwhile, manufacturing ecosystems in the region are increasingly geared towards modular facility designs and contract manufacturing partnerships to accommodate both biologics and device integration.

The Europe, Middle East & Africa landscape is characterized by regulatory fragmentation across multiple jurisdictions, each with nuanced expectations for device-drug combination submissions and clinical evidence for mucosal vaccines. This region sees pronounced interest in cold-chain independent formulations and powder formats, given logistical challenges in some markets. Stakeholders here often prioritize cost-effectiveness and public health procurement dynamics, which influences commercial pricing strategies and the design of scalable immunization campaigns.

Across the Asia-Pacific region, high population density, diverse disease burdens, and rapid expansions in biopharma manufacturing capacity create compelling case studies for scaled vaccine deployment and consumer-driven adoption of intranasal therapeutics. Local manufacturing incentives and active public-private alliances foster acceleration of clinical programs, while regional supply-chain strengths in device component production present opportunities for vertical integration. Taken together, these regions present differentiated pathways for market entry, partnership configuration, and regulatory sequencing that should be weighed against manufacturing footprint decisions and distribution models.

Strategic behaviors and competitive dynamics among pharmaceutical innovators, device designers, CDMOs, and biotech entrants that are defining leadership in intranasal delivery

Key industry participants span large multinational pharmaceutical developers, specialized device manufacturers, contract development and manufacturing organizations, and agile biotech innovators focusing on mucosal immunology and formulation science. Leading actors are pursuing several common strategic behaviors: integrating device and formulation development earlier in the pipeline to reduce late-stage compatibility risk, forming multi-disciplinary alliances with academic centers to leverage mechanistic mucosal immunity insights, and investing in scalable fill-finish capabilities that accommodate both liquid and powder vaccine formats. In addition, service providers are differentiating by offering combined regulatory and quality packages that reflect the unique demands of device-drug combination products.

Competitive dynamics emphasize IP cultivation around novel delivery mechanisms, mucoadhesive chemistries, and atomizer technologies, with a subset of players pursuing platform strategies that can be applied across analgesics, hormone therapies, and vaccine constructs. Investment in patient-centric design-ease of administration, dosing accuracy, and portability-has become a core metric for commercial success, particularly as homecare adoption rises. Finally, strategic M&A and licensing arrangements are frequently used to pair formulation expertise with route-to-market capabilities, enabling faster clinical translation while spreading development risk across partners.

Actionable strategic recommendations for aligning device co-development, supply-chain resilience, formulation choices, and evidence generation to accelerate clinical and commercial success

Industry leaders should adopt a multi-pronged approach that aligns scientific rigor with commercial pragmatism. First, prioritize integrated device and formulation development from the outset to avoid downstream compatibility issues that can delay regulatory submissions; early co-development reduces iteration cycles and supports cleaner clinical datasets. Second, diversify supplier networks for critical components and identify localized manufacturing partners to mitigate tariff and geopolitical risk, while simultaneously qualifying secondary vendors through parallel process validation to preserve trial continuity.

Third, invest in robust stability programs that evaluate liquid, gel, and powder options in parallel, because formulation choice directly influences cold-chain burden, distribution strategy, and patient acceptability. Fourth, pursue adaptive clinical designs and real-world evidence strategies that demonstrate both mucosal and systemic endpoints for vaccines and clear pharmacodynamic outcomes for therapeutic indications; this evidence will be pivotal for payers and public health purchasers. Fifth, cultivate strategic alliances across academia, device specialists, and CDMOs to accelerate platform maturation and share developmental risk. Finally, incorporate patient and provider experience metrics early to inform device ergonomics and training materials, ensuring that commercial rollout in homecare and outpatient settings is supported by clear usage guidance and adherence monitoring pathways.

Comprehensive research approach combining primary interviews, technical literature synthesis, regulatory analysis, and triangulation to validate actionable insights for intranasal programs

The research underpinning this executive summary synthesizes primary interviews, secondary literature, regulatory guidance, and technical validation to construct a robust, multi-dimensional understanding of intranasal delivery. Primary research included structured interviews with formulation scientists, device engineers, regulatory affairs professionals, procurement leads, and clinician end-users to capture practical constraints, adoption drivers, and emergent clinical priorities. Secondary sources comprised peer-reviewed literature on mucosal immunology, public regulatory guidance on combination products, and technical white papers on spray and powder delivery technologies to contextualize primary insights.

Data triangulation was implemented by cross-referencing interview findings with regulatory documentation and technical specifications from device manufacturers, ensuring consistency between claimed device performance and observed clinical requirements. Quality assurance steps included expert review panels and scenario stress-testing of supply-chain assumptions, particularly in relation to tariff and localization implications. Limitations of the methodology are acknowledged: rapidly evolving clinical data and commercial agreements can introduce change after the research cut-off, and while the approach emphasizes depth and cross-validation, specific contractual or proprietary manufacturing details may not be fully represented. Nonetheless, the methodology provides a comprehensive, evidence-based foundation for strategic decision-making across the intranasal product lifecycle.

A decisive synthesis underscoring the practical imperatives and strategic pathways required to translate intranasal innovations into clinically and commercially viable products

Intranasal delivery sits at a strategic inflection point where scientific potential meets pragmatic deployment challenges. Advances in formulation chemistry and device precision have expanded the modality's utility across vaccines and a range of therapeutic indications, while tariff shifts and supply-chain disruptions have elevated the importance of sourcing strategy and manufacturing footprint decisions. Segmentation analysis underscores that success depends on deliberate alignment among drug type, formulation format, device selection, dosage approach, intended application, and end-user context.

For program leaders and investors, the imperative is clear: integrate device and formulation decisions early, build resilient and localized supply chains where warranted, and generate evidence that resonates with both regulators and payers by addressing mucosal and real-world effectiveness endpoints. Executional excellence across these domains will differentiate leaders who can translate intranasal scientific advances into accessible, effective products for patients and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in mucoadhesive polymer systems for prolonged intranasal drug residence time
  • 5.2. Utilization of aerosolized nanocarriers for enhanced brain-targeted delivery through the nasal route
  • 5.3. Integration of 3D printing techniques for personalized intranasal dosage form fabrication
  • 5.4. Clinical progress of live attenuated intranasal COVID-19 vaccines showing improved mucosal immunity
  • 5.5. Emerging intranasal migraine therapies leveraging rapid onset small molecule formulations
  • 5.6. Expansion of intranasal insulin sprays for neurodegenerative disease treatment in clinical trials
  • 5.7. Scaled manufacturing of dry powder nasal vaccines using advanced spray freeze drying technologies
  • 5.8. Collaboration between pharmaceutical and device manufacturers to optimize nasal spray delivery systems
  • 5.9. Adoption of real-time imaging techniques to monitor intranasal deposition and absorption profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intranasal Drug & Vaccine Delivery Market, by Drug Type

  • 8.1. Analgesics
    • 8.1.1. Non-opioids
    • 8.1.2. Opioids
  • 8.2. Antihistamines
  • 8.3. Steroids
  • 8.4. Vaccines
    • 8.4.1. Inactivated Vaccines
    • 8.4.2. Live Attenuated Vaccines
    • 8.4.3. mRNA-based Vaccine

9. Intranasal Drug & Vaccine Delivery Market, by Formulation Type

  • 9.1. Gel Formulations
  • 9.2. Liquid Formulations
  • 9.3. Powder Formulations

10. Intranasal Drug & Vaccine Delivery Market, by Device Type

  • 10.1. Atomizer
  • 10.2. Nasal Dropper
  • 10.3. Nasal Spray

11. Intranasal Drug & Vaccine Delivery Market, by Dosage

  • 11.1. Multi-dose
  • 11.2. Unit-dose

12. Intranasal Drug & Vaccine Delivery Market, by Application

  • 12.1. Allergy Treatment
  • 12.2. Hormone Replacement
  • 12.3. Neurological Conditions
  • 12.4. Pain Management
  • 12.5. Psychiatric Disorders
  • 12.6. Therapeutic Drug Delivery

13. Intranasal Drug & Vaccine Delivery Market, by End-User

  • 13.1. Homecare
  • 13.2. Hospitals & Clinics
  • 13.3. Research & Academic Institution

14. Intranasal Drug & Vaccine Delivery Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Intranasal Drug & Vaccine Delivery Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Intranasal Drug & Vaccine Delivery Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Altimmune, Inc.
    • 17.3.2. AptarGroup, Inc.
    • 17.3.3. AstraZeneca PLC
    • 17.3.4. Bausch Health Companies Inc.
    • 17.3.5. Bayer AG
    • 17.3.6. Becton, Dickinson, and Company
    • 17.3.7. Bharat Biotech Ltd.
    • 17.3.8. Boehringer Ingelheim International GmbH.
    • 17.3.9. Catalent, Inc
    • 17.3.10. DCA Design International Limited
    • 17.3.11. Emergent BioSolutions Inc.
    • 17.3.12. GlaxoSmithKline PLC
    • 17.3.13. Hovione Limited
    • 17.3.14. Impel Pharmaceuticals LLC.
    • 17.3.15. Indivior PLC
    • 17.3.16. Intersect ENT by Medtronic plc
    • 17.3.17. Intertek Group PLC
    • 17.3.18. Johnson & Johnson Services, Inc.
    • 17.3.19. Kindeva Drug Delivery L.P.
    • 17.3.20. Merck & Co., Inc.
    • 17.3.21. Neurelis, Inc.
    • 17.3.22. Novartis AG
    • 17.3.23. OptiNose, Inc.
    • 17.3.24. Pfizer Inc.
    • 17.3.25. Recipharm AB.
    • 17.3.26. Sanofi S.A.
    • 17.3.27. Teleflex Incorporated
    • 17.3.28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MRNA-BASED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GEL FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ATOMIZER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL DROPPER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ALLERGY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY THERAPEUTIC DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 20